The Autism & Neuroscience division at the Simons Foundation is accepting applications for funding of courses or conferences. This year, courses and conferences that align with the scientific missions of any of the following programs will be prioritized: Simons Foundation Autism Research Initiative (SFARI), with a mission to advance the basic science of autism and related neurodevelopmental disorders, the Simons Collaboration on Plasticity and the Aging Brain (SCPAB), with a focus on healthy cognitive aging, and the Simons Collaboration on the Global Brain (SCGB), with a focus on the fields of systems and computational neuroscience.

The goal of the Shenoy Undergraduate Research Fellowship in Neuroscience (SURFiN) program is to spark and sustain interest in neuroscience among undergraduate students who have not had access to research training opportunities. SURFiN provides funds for paid, in-person undergraduate research assistantships during the academic year to students living near Simons Foundation-supported laboratories in the U.S., Canada and Europe.

Grants awarded through this request for applications (RFA) are intended to recharge and extend a consortium of researchers using rats as an experimental system to advance our understanding of the behavioral and circuit neuroscience mechanisms underlying autism and related neurodevelopmental disorders (NDD).

The Linking Early Neurodevelopment to Neural Circuit Outcomes RFA aims to bridge the gap in our understanding of whether and how developmental phenotypes caused by autism risk gene mutation lead to altered circuit formation and function. We strongly encourage proposals involving close collaboration between investigators from a range of backgrounds, such as developmental neurobiologists and circuit neuroscientists, in order to convincingly demonstrate causal links between disparate phenotypes in the chosen model(s).

The goal of the Pilot Award is to provide early support for exploratory ideas considered higher risk but with the potential for transformative results, particularly those with novel hypotheses for autism. This funding mechanism is particularly suitable for investigators new to the autism field, though we encourage applicants to consult with experts in autism research to ensure their projects are relevant to the human condition. We encourage applications that propose research to link genetic or other ASD risk factors to molecular, cellular, circuit or behavioral mechanisms and set the stage for development of novel interventions, including work in human subjects.

The goal of the Pilot Progression Award is to provide continuing support for projects initiated during SFARI Pilot awards that have advanced significantly and produced insights that justify an extension.

Grants awarded through the Cross-Species Studies of ASD RFA were intended to support multi-disciplinary teams of PIs with expertise in both human and animal research to perform coordinated cross-species studies to advance our understanding of ASD-relevant behaviors and their underlying neurobiological mechanisms, with the potential for developing novel biomarkers or interventions.

The Human Cognitive and Behavioral Science RFA prioritized research that produces foundational knowledge about the neurobehavioral differences associated with ASD. These projects were expected to inform or relate to the development and refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis was placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better characterize phenotypic and neurobiological variability within and across individuals with ASD.

Grants awarded through this RFA were intended to improve our understanding of the molecular and cellular consequences of genetic risk for ASD, and to provide a foundation for the development of new therapies. Special emphasis was placed on the use of scalable methods, especially as applied to genes that are suitable targets for genetic therapies.